文献速递妇科

原发部位真的重要吗?对原发部位不明的黏液性卵巢癌(MO-CUP)进行特征分析以个体化治疗并指导临床试验设计

Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
PubMed 文献 · Gynecol Oncol · 2018-07-25

本研究分析333例原发部位不明的黏液性卵巢癌(MO-CUP)肿瘤特征数据,其中38例交界性肿瘤、295例浸润性癌。浸润性癌常见突变为KRAS(60%)、TP53(38%)、PIK3CA(13%)和PTEN(9%);KRAS突变型浸润性癌胸苷酸合成酶表达较低(p=0.01)、TUBB3表达较高(p=0.01)。作者认为在MO-CUP中应聚焦识别治疗靶点、个体化治疗并设计不依赖原发部位的临床试验。

要点

  • 333例MO-CUP中交界性肿瘤38例、浸润性癌295例。
  • 浸润性癌最常见突变为KRAS(60%)、TP53(38%)、PIK3CA(13%)和PTEN(9%)。
  • KRAS突变型浸润性癌胸苷酸合成酶表达较低(p=0.01)、TUBB3表达较高(p=0.01)。

核心结论

  • 作者认为,鉴于罕见卵巢癌亚型组织学特异性试验招募困难,在MO-CUP中可能更重要的是聚焦识别潜在治疗靶点、个体化治疗并设计不依赖原发部位的临床试验。

研究设计与样本

  • 研究分析了一个大型去标识化、多平台肿瘤特征分析数据集,纳入提交至Caris Life Sciences的MO-CUP病例,并富集晚期和复发案例。
  • 可用数据包括45基因二代测序(NGS)面板、HER2和cMET基因扩增以及18种药物敏感性/耐药性免疫组化(IHC)标志物。
  • 共分析333例患者的黏液性肿瘤,包括38例交界性肿瘤和295例浸润性癌。

主要发现

  • 在128例浸润性癌子集中,最常见突变为KRAS(60%)、TP53(38%)、PIK3CA(13%)和PTEN(9%)。
  • 交界性肿瘤较浸润性癌有更高的BRAF突变率以及PGP和TOP2A过表达率。
  • KRAS突变型浸润性癌较KRAS野生型肿瘤胸苷酸合成酶表达较低(p=0.01)、TUBB3表达较高(p=0.01)。

临床怎么用

  • 作者认为,在MO-CUP中可能更重要的是聚焦识别潜在治疗靶点、个体化治疗并设计不依赖原发部位的临床试验,以克服组织学特异性试验招募困难的问题。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Advanced stage mucinous ovarian cancers are diagnostically and therapeutically challenging. Histotype specific trials have failed due to low recruitment after excluding non-ovarian primaries. Mucinous ovarian cancers are commonly metastatic from other sites however lack definitive diagnostic markers. We suggest a classification of mucinous ovarian cancers of uncertain primary origin 'MO-CUPs' in clinical trials. This study aims to identify drug targets to guide treatment and future trials. METHODS: We analyzed a large de-identified, multi-platform tumor profiling dataset of MO-CUPs enriched for advanced stage and recurrent cases submitted to Caris Life Sciences. Available data included a 45-gene next-generation sequencing (NGS) panel, gene amplification of HER2 and cMET and 18 immunohistochemical (IHC) markers of drug sensitivity/resistance. RESULTS: Mucinous tumors from 333 patients were analyzed, including 38 borderline tumors and 295 invasive cancers. The most common mutations in a subset (n = 128) of invasive cancers were KRAS (60%), TP53 (38%), PIK3CA (13%) and PTEN (9%). Borderline tumors had higher rates of BRAF mutations, and PGP and TOP2A overexpression than invasive cases. KRAS mutant invasive cancers had lower expression of thymidylate synthase (p = 0.01) and higher expression of TUBB3 (p = 0.01) than KRAS wildtype tumors. CONCLUSIONS: To our knowledge, this is the largest series profiling mucinous ovarian cancers and almost certainly includes cases of ovarian and non-ovarian origin. Given the difficulty recruiting patients to histotype-specific trials in rare subsets of ovarian cancer, it may be more important to focus on identifying potential treatment targets and to personalise treatment and design clinical trials in MO-CUPS agnostic of primary site to overcome these issues.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Meagher NS, Schuster K, Voss A, et al. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials. Gynecol Oncol. 2018. PMID: 30054102. doi:10.1016/j.ygyno.2018.07.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。